Table 2

 Characteristics of the cohort (n = 184) at inclusion and at three and six months

Baseline3 Months6 Months
Values for median and (25th to 75th centile). Physician’s global assessment is recorded at a 5 point Likert scale.
*p<0.001 v baseline.
DAS 28; 28 joint disease activity score; DMARD, disease modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire; RF, rheumatoid factor; SDAI; simple disease activity index; VAS, visual analogue scale.
Numbers184184150
Male/female46/138
Disease duration (years)12 (0 to 55)
Age at inclusion (years)56 (20 to 84)
Previous number of DMARDs3 (2 to 5)
Steroid dose (mg/week)35 (17 to 57)35 (0 to 53)*18 (0 to 35)*
ESR (mm/h)31.5 (20 to 54)20 (12 to 34)*20 (10 to 38)*
C reactive protein (mg/litre)21 (10 to 42)9 (1 to 22)*9 (1 to 23)*
VAS pain (mm)64 (47 to 78)34 (16 to 55)*29 (15 to 55)*
VAS global (mm)66.5 (49 to 81)34 (15 to 55)*29 (15 to 57)*
Physician’s global assessment2 (2 to 3)1 (1 to 2)*1 (1 to 2)*
28 tender joint count7.5 (3 to 13)2 (0 to 5.5)*2 (0 to 6)*
28 swollen joint count9 (5 to 12)3 (1 to 6)*3 (0 to 6)*
HAQ1.4 (1 to 1.9)1.1 (0.6 to 1.6)*1.1 (0.6 to 1.6)*
DAS 285.6 (4.7 to 6.4)3.8 (2.8 to 4.8)*3.7 (2.7 to 4.8)*
SDAI31 (24 to 41)14 (9 to 24)*13 (7 to 22)*